194 related articles for article (PubMed ID: 30223034)
1. Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy.
Pattanayak R; Barua A; Das A; Chatterjee T; Pathak A; Choudhury P; Sen S; Saha P; Bhattacharyya M
Eur J Pharm Sci; 2018 Dec; 125():39-53. PubMed ID: 30223034
[TBL] [Abstract][Full Text] [Related]
2. Selective binding of a bioactive porphyrin-based photosensitizer to the G-quadruplex from the KRAS oncogene promoter.
Caterino M; D'Aria F; Kustov AV; Belykh DV; Khudyaeva IS; Starseva OM; Berezin DB; Pylina YI; Usacheva T; Amato J; Giancola C
Int J Biol Macromol; 2020 Feb; 145():244-251. PubMed ID: 31870869
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design and evaluation of synthetic porphyrin derivatives as G-quadruplex stabilizing anticancer agents.
Bhadane RN; Meshram DB; Gilhotra RM
J Exp Ther Oncol; 2017 Nov; 12(2):103-111. PubMed ID: 29161777
[TBL] [Abstract][Full Text] [Related]
4. Critical role of hnRNP A1 in activating KRAS transcription in pancreatic cancer cells: A molecular mechanism involving G4 DNA.
Cogoi S; Rapozzi V; Cauci S; Xodo LE
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1389-1398. PubMed ID: 27888145
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic Therapy for
Ferino A; Nicoletto G; D'Este F; Zorzet S; Lago S; Richter SN; Tikhomirov A; Shchekotikhin A; Xodo LE
J Med Chem; 2020 Feb; 63(3):1245-1260. PubMed ID: 31930916
[TBL] [Abstract][Full Text] [Related]
6. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription.
Cogoi S; Xodo LE
Nucleic Acids Res; 2006; 34(9):2536-49. PubMed ID: 16687659
[TBL] [Abstract][Full Text] [Related]
7. A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer.
Ohnmacht SA; Marchetti C; Gunaratnam M; Besser RJ; Haider SM; Di Vita G; Lowe HL; Mellinas-Gomez M; Diocou S; Robson M; Šponer J; Islam B; Pedley RB; Hartley JA; Neidle S
Sci Rep; 2015 Jun; 5():11385. PubMed ID: 26077929
[TBL] [Abstract][Full Text] [Related]
8. RNA G-Quadruplexes in Kirsten Ras (KRAS) Oncogene as Targets for Small Molecules Inhibiting Translation.
Miglietta G; Cogoi S; Marinello J; Capranico G; Tikhomirov AS; Shchekotikhin A; Xodo LE
J Med Chem; 2017 Dec; 60(23):9448-9461. PubMed ID: 29140695
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent light-up acridine orange derivatives bind and stabilize KRAS-22RT G-quadruplex.
Carvalho J; Pereira E; Marquevielle J; Campello MPC; Mergny JL; Paulo A; Salgado GF; Queiroz JA; Cruz C
Biochimie; 2018 Jan; 144():144-152. PubMed ID: 29129745
[TBL] [Abstract][Full Text] [Related]
10. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice.
Cogoi S; Zorzet S; Rapozzi V; Géci I; Pedersen EB; Xodo LE
Nucleic Acids Res; 2013 Apr; 41(7):4049-64. PubMed ID: 23471001
[TBL] [Abstract][Full Text] [Related]
11. Spectroscopic investigation of the interaction between G-quadruplex of KRAS promoter sequence and three isoquinoline alkaloids.
Wen LN; Xie MX
Spectrochim Acta A Mol Biomol Spectrosc; 2017 Jan; 171():287-296. PubMed ID: 27565766
[TBL] [Abstract][Full Text] [Related]
12. Targeting pancreatic cancer with a G-quadruplex ligand.
Gunaratnam M; de la Fuente M; Hampel SM; Todd AK; Reszka AP; Schätzlein A; Neidle S
Bioorg Med Chem; 2011 Dec; 19(23):7151-7. PubMed ID: 22041170
[TBL] [Abstract][Full Text] [Related]
13. Interaction of KRAS G-quadruplex with natural polyphenols: A spectroscopic analysis with molecular modeling.
Pattanayak R; Basak P; Sen S; Bhattacharyya M
Int J Biol Macromol; 2016 Aug; 89():228-37. PubMed ID: 27130653
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a new G-quadruplex forming region within the kRAS promoter as a transcriptional regulator.
Morgan RK; Batra H; Gaerig VC; Hockings J; Brooks TA
Biochim Biophys Acta; 2016 Feb; 1859(2):235-45. PubMed ID: 26597160
[TBL] [Abstract][Full Text] [Related]
15. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
16. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
17.
D'Aria F; Pagano B; Petraccone L; Giancola C
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466280
[TBL] [Abstract][Full Text] [Related]
18. Structural polymorphism within a regulatory element of the human KRAS promoter: formation of G4-DNA recognized by nuclear proteins.
Cogoi S; Paramasivam M; Spolaore B; Xodo LE
Nucleic Acids Res; 2008 Jun; 36(11):3765-80. PubMed ID: 18490377
[TBL] [Abstract][Full Text] [Related]
19. The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells.
Pramanik S; Chen Y; Song H; Khutsishvili I; Marky LA; Ray S; Natarajan A; Singh PK; Bhakat KK
Nucleic Acids Res; 2022 Apr; 50(6):3394-3412. PubMed ID: 35286386
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
